8-K filing — Retension Pharmaceuticals, Inc. (RTSN)
Filed: 2026-10-13 AccNo: 0001213900-26-109024 Size: 441 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Reported Earlier, Retension Pharmaceuticals Prices Upsized Initial Public Offering Of 3.75M Shares At $12.00 Each For $45.0M Gross Proceeds To Fund RTN-001 Phase 2b And Phase 3 Hypertension Trials
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading